2023 World Conference on Lung Cancer (Posters)-EP14.01. Does Delaying Surgery Following Induction Chemotherapy Compromise Survival in Patients with Malignant Pleural Mesothelioma?

EP14.01. Does Delaying Surgery Following Induction Chemotherapy Compromise Survival in Patients with Malignant Pleural Mesothelioma? - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate whether delaying surgery following induction chemotherapy would compromise survival outcomes in patients with malignant pleural mesothelioma (MPM). The researchers queried the National Cancer Database for patients with favorable prognostic factors considered for surgery and compared those who had immediate or delayed surgery to those who did not have surgery and those who were treated with surgery only. <br /><br />The study included 4,294 patients, with the majority undergoing induction chemotherapy followed by no surgery. The proportion of patients undergoing both immediate and delayed surgery increased over the last decade, but delayed surgery remained more common. There were no significant differences in baseline characteristics between the immediate and delayed surgery groups. <br /><br />The results showed that delaying surgery following induction chemotherapy did not compromise overall survival in patients with MPM. Higher comorbidity scores were associated with increased risk of death, but timing of surgery was not. This finding held true even after performing a sensitivity analysis using 6 months as the definition of delayed surgery.<br /><br />In conclusion, this study suggests that delaying surgery following induction chemotherapy is feasible and does not compromise overall survival in patients with MPM. The findings contribute to understanding the optimal timing of surgical resection in the multimodal treatment of MPM.

Asset Subtitle

Lye-Yeng Wong

Meta Tag

Speaker Lye-Yeng Wong

Topic Mesothelioma, Thymoma & Other Thoracic Tumors

Keywords

surgery

delayed surgery

induction chemotherapy

malignant pleural mesothelioma

MPM

survival outcomes

National Cancer Database

prognostic factors

baseline characteristics

comorbidity scores